Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Bromfenac

Copy Product Info
😃Good
Catalog No. T61010Cas No. 91714-94-2

Bromfenac can be used in the research of ocular inflammation that is a potent and orally active COX inhibitor with IC50 values of 5.56 and 7.45 nM for COX-1 and COX-2, respectively [1].

Bromfenac

Bromfenac

Copy Product Info
😃Good
Catalog No. T61010Cas No. 91714-94-2
Bromfenac can be used in the research of ocular inflammation that is a potent and orally active COX inhibitor with IC50 values of 5.56 and 7.45 nM for COX-1 and COX-2, respectively [1].
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
25 mg$1,5201-2 weeks1-2 weeks
50 mg$1,9801-2 weeks1-2 weeks
100 mg$2,5001-2 weeks1-2 weeks
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
Bromfenac can be used in the research of ocular inflammation that is a potent and orally active COX inhibitor with IC50 values of 5.56 and 7.45 nM for COX-1 and COX-2, respectively [1].
Targets&IC50
COX-1 (human):5.56 nM, COX-2 (human):7.45 nM
In vitro
Bromfenac, at concentrations ranging from 0 to 80 μg/mL over 24 hours, inhibits the transforming growth factor-β2 (TGF-β2)-induced epithelial-mesenchymal transition (EMT) in HLEC-B3 cells in a dose-dependent manner [2]. Similarly, at a concentration of 80 μg/mL for 48 hours, it suppresses TGF-β2-induced EMT in human anterior capsules, as evidenced by cell viability assays on TGF-β2-treated human anterior capsules, and cell migration assays on HLEC-B3 cells. These assays further confirm that bromfenac effectively prevents the TGF-β2-induced cell migration and over-expression of EMT markers in primary lens epithelial cells (LECs) and HLEC-B3 cells, respectively [2].
In vivo
Bromfenac demonstrates significant anti-inflammatory effects in various concentrations and application methods across animal models. In rats, concentrations as low as 0.1% with 4 hours of pretreatment and 0.32% with 18 hours of pretreatment, applied to the backs, show noteworthy anti-inflammatory activity. A similar dose-related effect is observed when applied to the rats' paws. Notably, a concentration range of 0.032-1.0% applied to guinea pigs' skin exposed to UV light reveals that Bromfenac is 26 times more potent than indomethacin in reducing erythema. Additionally, a consistent dose and time-dependent reduction in paw volume were achieved in rats with applications on the uninjected paw, demonstrating systemic effects. In the context of abdominal constriction responses to acetylcholine in mice, a 0.32% concentration applied to the abdomen effectively blocks these responses. Furthermore, Bromfenac eyedrop instillation at 0.09% concentration, administered twice daily for four weeks, modestly reduces corneal staining in a progressive manner over the treatment period. These findings underscore Bromfenac's broad potential in anti-inflammatory applications across different models and conditions.
Chemical Properties
Molecular Weight334.16
FormulaC15H12BrNO3
Cas No.91714-94-2
SmilesNC1=C(C=CC=C1CC(O)=O)C(=O)C1=CC=C(Br)C=C1
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy Bromfenac | purchase Bromfenac | Bromfenac cost | order Bromfenac | Bromfenac chemical structure | Bromfenac in vivo | Bromfenac in vitro | Bromfenac formula | Bromfenac molecular weight